Could Sarepta Therapeutics’ (SRPT) New siRNA Data Mark a Turning Point Beyond Duchenne Therapies?

• Earlier this week, Sarepta Therapeutics reported the first human data from its SRP-1001 and SRP-1003 siRNA programs in FSHD1 and DM1, showing dose-dependent muscle exposure, target knockdown after a single dose, and a generally favorable tolerability profile in ongoing Phase 1/2 trials.
• The results offer early proof-of-concept for Sarepta’s avß6 integrin-targeted delivery platform, potentially broadening its rare disease franchise beyond Duchenne gene therapy and exon-skipping drugs.
• Next, we’ll examine how this early proof-of-concept for Sarepta’s avß6 integrin-targeted siRNA platform could reshape its investment narrative.

Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

Sarepta Therapeutics Investment Narrative Recap

To own Sarepta today, you have to believe its genetic medicine platforms can translate into durable, commercial rare disease franchises, while the company manages safety concerns around ELEVIDYS and works toward more traditional approvals for its Duchenne treatments. This week’s positive siRNA data reinforces the long-term diversification story, but in my view it does not materially change the near term focus on ELEVIDYS safety, site capacity constraints, and the upcoming AMONDYS 45 / VYONDYS 53 sNDA submissions.

The most relevant recent announcement alongside the siRNA update is Sarepta’s plan to submit supplemental NDAs to convert AMONDYS 45 and VYONDYS 53 from accelerated to traditional approvals, backed by ESSENCE data and real world evidence. If successful, that could stabilize a key part of the Duchenne franchise while newer platforms like the avß6 integrin targeted siRNA programs mature, potentially balancing the risk concentration around ELEVIDYS and gene therapy infusions.

Yet, despite the encouraging siRNA readout, investors should still be aware of how safety scrutiny around ELEVIDYS could affect...

Read the full narrative on Sarepta Therapeutics (it's free!)

Sarepta Therapeutics' narrative projects $1.4 billion revenue and $100.2 million earnings by 2029. This requires a 13.3% yearly revenue decline and an earnings increase of about $813.6 million from -$713.4 million today.

Uncover how Sarepta Therapeutics' forecasts yield a $20.61 fair value, a 5% downside to its current price.

Exploring Other Perspectives

Some of the lowest analyst estimates were already cautious, assuming about US$2.9 billion of revenue and US$616.4 million of earnings by 2028, and your view on whether ELEVIDYS safety scrutiny and site bottlenecks persist after this siRNA news may lead you to a very different conclusion about Sarepta’s path than those pessimists.

Explore 7 other fair value estimates on Sarepta Therapeutics - why the stock might be worth just $20.61!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Sarepta Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Sarepta Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Sarepta Therapeutics' overall financial health at a glance.

Searching For A Fresh Perspective?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Find 61 companies with promising cash flow potential yet trading below their fair value.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 26 best rare earth metal stocks of the very few that mine this essential strategic resource.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com